Cross-Cancer Type Evaluation of Potential Interstitial Lung Disease Complications of Immune Checkpoint Inhibitors Using JADER
Biological and Pharmaceutical Bulletin · 2024
DOI: 10.1248/bpb.b24-00130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2024. Verfasst von Kazuma Koga und 2 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Clinical Pharmacy, Shujitsu University. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Clinical Pharmacy, Shujitsu University.
- Department of Pharmacy, NHO Okayama Medical Center.
Zitieren
APA
Koga, K., Tasaka, Y., & Nawa, H. (2024). Cross-Cancer Type Evaluation of Potential Interstitial Lung Disease Complications of Immune Checkpoint Inhibitors Using JADER. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b24-00130
Vancouver
Koga K, Tasaka Y, Nawa H. Cross-Cancer Type Evaluation of Potential Interstitial Lung Disease Complications of Immune Checkpoint Inhibitors Using JADER. Biological and Pharmaceutical Bulletin. 2024. doi:10.1248/bpb.b24-00130
BibTeX
@article{Koga2024,
author = {Koga, Kazuma and Tasaka, Yuichi and Nawa, Hideki},
title = {Cross-Cancer Type Evaluation of Potential Interstitial Lung Disease Complications of Immune Checkpoint Inhibitors Using JADER},
journal = {Biological and Pharmaceutical Bulletin},
year = {2024},
doi = {10.1248/bpb.b24-00130}
}
EUVIMED